PPID study finds same lifespan, but more medical events in horses

Horses diagnosed with pituitary pars intermedia dysfunction, or PPID, may live just as long as similar horses without the condition, but they appear to face more medical problems along the way. That’s the key takeaway from a new study highlighted by The Horse and discussed on AVMA’s Veterinary Vertex podcast. In the study, researchers found no shorter life expectancy in horses with PPID, but they did find higher odds of poor healing, dental disease, hyperinsulinemia-associated laminitis, and NSAID use in affected horses. The paper adds nuance to a condition often framed mainly around survival, suggesting the bigger burden may be morbidity, not lifespan. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For equine veterinarians, the findings support a more proactive, whole-horse management approach after diagnosis. Current PPID recommendations already emphasize that treatment can improve quality of life without necessarily extending lifespan, and they call for ongoing monitoring of endocrine control, insulin dysregulation risk, laminitis, dental health, and other age-related comorbidities. In practice, that means a PPID diagnosis should trigger not just pergolide discussions, but a broader preventive care plan and regular reassessment. (idppid.com)

What to watch: Expect follow-up discussion around how primary care vets monitor PPID horses over time, especially for laminitis risk, dental disease, and treatment response. (pubmed.ncbi.nlm.nih.gov)